Results 71 to 80 of about 19,276 (249)

Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects

MedComm, Volume 7, Issue 1, January 2026.
The management of cancer and tissue regeneration remains a substantial challenge to global health. Organoids, which are stem cell‐derived three‐dimensional multicellular structures, are revolutionizing biomedical research. Therefore, this review highlights their applications in cancer research and regenerative medicine, while discussing current ...
Ruiyang Li, Yuezhou Wu, Zhu'anzhen Zheng, Fengjin Zhou, Ke Xu, Jiacan Su   +5 more
wiley   +1 more source

Physical Function and Quality of Life After Resection of Mobile Spine Chondrosarcoma. [PDF]

, 2019
Study Design:Retrospective cohort study. Objectives:(1) To assess patient-reported outcomes-physical function, pain, and quality of life-in patients who underwent resection of a mobile spine chondrosarcoma.
Chen, Yen-Lin E, DeLaney, Thomas F, Hartveldt, Stefan, Hornicek, Francis J, Janssen, Stein J, Paulino Pereira, Nuno Rui, Schwab, Joseph H, Stoop, Nicky   +7 more
core   +1 more source

Microstructural profiling and habitat analysis to characterize treatment outcome patterns in Sacral Chordomas treated with carbon ions

Medical Physics, Volume 53, Issue 1, January 2026.
Abstract Background Sacral chordoma (SC) is a rare and locally aggressive tumor, characterized by a high risk of local recurrence (LR). Advanced imaging biomarkers capturing tumor heterogeneity and treatment response may help refine patient stratification and improve outcomes.
Letizia Morelli, Giovanni Parrella, Marco Rotondi, Silvia Molinelli, Giuseppe Magro, Sara Imparato, Agnieszka Chalaszczyk, Maria Rosaria Fiore, Chiara Paganelli, Ester Orlandi, Guido Baroni   +10 more
wiley   +1 more source

EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. [PDF]

, 2016
Chordoma is a rare malignant bone tumour with a poor prognosis and limited therapeutic options. We undertook a focused compound screen (FCS) against 1097 compounds on three well-characterized chordoma cell lines; 154 compounds were selected from the ...
Amary, F, Barnard, M, Brüderlein, S, Cottone, L, Drewry, DH, Flanagan, AM, Guppy, N, Jorgensen, M, Leite, AP, Leithner, A, Möller, P, Pillay, N, Scheipl, S, Smith, JA, Strauss, SJ, Tirabosco, R, Turlais, F, Ye, H, Zuercher, WJ   +18 more
core   +1 more source

Inter‐fraction dose and LET robustness in LET‐optimized proton therapy for pediatric, adolescent and young adult intracranial tumors

Medical Physics, Volume 53, Issue 1, January 2026.
Abstract Background Although pediatric, adolescent and young adults (AYA) patients are known to be eligible for proton therapy, the presence of high linear energy transfer (LET) in critical structures, such as the brainstem, could lead to an increased risk of toxicity.
Alfredo Mirandola, Matteo Bagnalasta, Giuseppe Magro, Alessia Bazani, Silvia Molinelli, Vittoria Pavanello, Eleonora Rossi, Stefania Russo, Luca Trombetta, Alessandro Vai, Francesca Colombo, Ester Orlandi, Mario Ciocca, Sabina Vennarini   +13 more
wiley   +1 more source

Immune microenvironment and immunotherapy for chordoma

Frontiers in Oncology
Chordoma, as a rare, low-grade malignant tumor that tends to occur in the midline of the body, grows slowly but often severely invades surrounding tissues and bones.
Yujia Chen, Hongwei Zhang
doaj   +1 more source

Reply to Commentary on “Sacral Nerves Reconstruction After Surgical Resection of a Large Sacral Chordoma Restores the Urinary and Sexual Function and the Anal Continence” [PDF]

, 2022
Luigi Valentino Berra
openalex   +1 more source

Patient‐specific quality assurance at the Heidelberg Ion Beam Therapy Center: 10 years experience in treatment plan verification

Medical Physics, Volume 53, Issue 1, January 2026.
Abstract Background To ensure accurate, safe, and reproducible patient treatments, it is essential to have precise knowledge and a solid understanding of patient‐specific quality assurance (PSQA). For many years, the delivery of doses to all patients has been verified using dosimetric measurements.
Abdallah Qubala, Christian P. Karger, Julian Horn, Marcus Winter, Malte Ellerbrock, Oliver Jäkel, Katrin Henkner   +6 more
wiley   +1 more source

Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT

Cancer Cell International, 2019
Background Tripartite motif-containing protein 11 (TRIM11), a member of RING family of E3 ubiquitin ligases, is identified as an oncogene in certain human tumors. However, the detailed biological function of TRIM11 in chordoma is still unclear.
Bin Wang, Gang Wang, Qingfeng Wang, Ziqiang Zhu, Yunqing Wang, Kangwu Chen, Huilin Yang   +6 more
doaj   +1 more source

Molecular features and vulnerabilities of recurrent chordomas

Journal of Experimental & Clinical Cancer Research, 2021
Background Tumor recurrence is one of the major challenges in clinical management of chordoma. Despite R0-resection, approximately 50% of chordomas recur within ten years after initial surgery.
Carolin Seeling, André Lechel, Michael Svinarenko, Peter Möller, Thomas F. E. Barth, Kevin Mellert   +5 more
doaj   +1 more source